medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 1

<< Back Next >>

Med Int Mex 2018; 34 (1)

Correlation between glomerular hyperfiltration and proteinuria in medium age smoking patients with no other comorbidities

Piña-Gorráez JR, García-López VH, Elizalde-Barrera CI, Arias-Sánchez B

Language: Spanish
References: 17
Page: 29-37
PDF size: 272.20 Kb.


ABSTRACT

Background: In Mexico the reports mention between 114 and 122 daily deaths associated with smoking. In 2011, Hallan and Orth published the results of a 10-year follow-up of more than 65,000 participants, concluding that the risk of developing renal failure is 3 to 4 times higher in smokers than in non-smokers.
Objective: To demonstrate how the use of tobacco in patients without comorbidities may favor glomerular hyperfiltration, thus increasing the risk of chronic kidney disease.
Material and Method: A cross-sectional, analytical, prospective study was conducted with patients from the Xoco General Hospital, Mexico City; they were divided into 2 groups. Blood samples were taken to obtain the serum creatinine and urea values, using the MDRD and CKD formulas. EPI estimated the glomerular filtration rate. Statistical analysis was performed with the SPSS V21 program.
Results: There were included 152 patients. Majority of the smoking population had high dependence with 20 cases and a prevalence of 27%. With a value of p = 0.023 for glomerular filtration rate (GFR) by MDRD and p = 0.006 for CKD-EPI. They had statistically significant differences. A statistically significant positive correlation (r = 0.413, p ‹ 0.01) between the smoking index and the GFR measured by MDRD was demonstrated in this study. Statistically significant positive correlation (r = 0.238, p = 0.041) was also found between smoking index and GFR measured by CKD-EPI.
Conclusion: Smoking causes high glomerular hyperfiltration compared to not-smoking subjects; this relation is dosis-dependent.


REFERENCES

  1. Rivero S, Cortés R, Arriaga Z. Encuesta de Tabaquismo en jóvenes en México. México: Instituto Nacional de Salud Pública, 2009.

  2. Franco F, Tirado L, Venado A, Moreno J y col. Una estimación indirecta de las desigualdades actuales y futuras en la frecuencia de la enfermedad renal crónica terminal en México. Salud Pub Mex 2011;53:SS506-515.

  3. Arreola J, Rincón R, Cruz C, Belmont T. Funcionamiento de las fórmulas MDRD-IDMS y CKD-EPI, en individuos mexicanos con función renal normal. Revista Nefrología 2014;34:591-598.

  4. Stephan R, Eberhard R, Schrier R. The renal risks of smoking. Kidney Int 1997;51:1669-1677.

  5. Halimi J, Giraudeau B, Caces E, Nivet H, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000;58:1285-1292.

  6. Yoon HJ, Park M, Yoon H, Son KY, Cho B, Kim S. The differential effect of cigarette smoking on glomerular filtration rate and proteinuria in an apparently healthy population. Hypertens Res 2009;32:214-219.

  7. Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int. 2008 Jun;73(11):1216-9. doi: 10.1038/ ki.2008.36. Epub 2008 Mar 5. Review

  8. Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol 2013;4:516-523.

  9. Elihimas Júnior UF, Elihimas HC, Lemos VM, Leão Mde A, Sá MP, França EE, et al. Smoking as risk factor for chronic kidney disease: systematic review. J Bras Nephrol 2014;36:519-528.

  10. Satirapoj B, Adler SG. Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract 2014;3:121-131.

  11. Jain G, Jaimes EA. Nicotine signaling and progression of chronic kidney disease in smokers. Biochem Pharmacol 2013;8:1215-23.

  12. Zeng J, Yang S, Wu L. Prevalence of passive smoking in the community population aged 15 years and older in China: a systematic review and meta-analysis. Br Med J 2017;6(4):5-11.

  13. Radcliffe NJ, Seah JM, Clarke M. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Inv 2017;8:6-18.

  14. Sheen YJ, Sheu WH. Risks of rapid decline renal function in patients with type 2 diabetes. World J Diabetes 2014;6:835-836.

  15. Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM. Diabetic kidney disease: from physiology to therapeutics. J Physiol 2014;18:3997-4012.

  16. Lunyera J, Mohottige D, Von Isenburg M. CKD of uncertain etiology: A systematic review. Clin J Am Soc Nephrol 2014;3:379-385.

  17. Morales J. Drogas nefrotóxicas. Revista Médica Clínica Condes 2010;3:623-624.




2020     |     www.medigraphic.com